Oric Pharmaceuticals, Inc. (ORIC) Institutional Ownership

Ownership Summary

A total of 160 institutions have reported a stake in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) as of December 2025, according to recent 13F filings with the SEC.

• The collective stake of institutional investors in Oric Pharmaceuticals moved to 117.7% in December 2025, a shift up from the 107.9% reported for September 2025.
• Quarterly data indicates a 13.46% shift in institutional share volume, and the annual owner count reflects an increase of 22.14%.
• The latest 13F cycle for Oric Pharmaceuticals reveals that of 160 total investors, 101 funds grew their exposure, whereas 33 reduced theirs and 26 made no changes.
• Collectively, institutional investors increased their stake in Oric Pharmaceuticals to 116.23Mn shares as of December 2025, a change that is up by 13.79Mn shares quarter on quarter and up 40.23Mn shares year over year.
• As of December 31, 2025, Nextech Invest, Ltd. held Oric Pharmaceuticals's largest shareholding position with over 7.16Mn shares, representing 7.25% of total outstanding shares.
• Among the most significant buyers of Oric Pharmaceuticals during December 2025 were Paradigm Biocapital Advisors LP (2.40Mn), STATE STREET CORP (1.85Mn), CITADEL ADVISORS LLC (1.24Mn), Qube Research & Technologies Ltd (1.21Mn), GOLDMAN SACHS GROUP INC (1.03Mn).
• Leading sellers of Oric Pharmaceuticals stock in December 2025 included Vivo Capital, LLC (1.01Mn), VR Adviser, LLC (920.65K), SILVERARC CAPITAL MANAGEMENT, LLC (832.20K), JPMORGAN CHASE & CO (813.74K), BALYASNY ASSET MANAGEMENT L.P. (569.10K).
• The top 10 institutional holders of Oric Pharmaceuticals for the quarter ending December 2025 included Nextech Invest, Ltd. (7.16Mn), EcoR1 Capital, LLC (6.73Mn), VIKING GLOBAL INVESTORS LP (6.57Mn), BlackRock, Inc. (5.87Mn), VR Adviser, LLC (5.68Mn), PFIZER INC (5.38Mn), VANGUARD GROUP INC (4.54Mn), SR ONE CAPITAL MANAGEMENT, LP (4.51Mn), ALKEON CAPITAL MANAGEMENT LLC (4.50Mn), STATE STREET CORP (4.26Mn).